ProfileGDS5678 / 1437137_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 38% 40% 39% 54% 36% 34% 36% 37% 68% 78% 68% 61% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9099438
GSM967853U87-EV human glioblastoma xenograft - Control 22.8732338
GSM967854U87-EV human glioblastoma xenograft - Control 32.9104440
GSM967855U87-EV human glioblastoma xenograft - Control 42.8256439
GSM967856U87-EV human glioblastoma xenograft - Control 53.289554
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9052336
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8250234
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8103136
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8161837
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1572568
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.351278
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1394668
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6491661
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4758171